Emmaus Life Sciences, Inc.

What they do

Emmaus develops, markets and sells Endari (prescription grade L-glutamine oral powder), its sole product, approved by the FDA for sickle cell disease patients age five and older. It sells Endari in the U.S. through nonexclusive distributors and in the Middle East North Africa region through exclusive local distributors. Under a December 2025 License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (NIT), which became effective May 15, 2026, NIT holds an exclusive license to market, sell and distribute Endari and any generic equivalents in sickle cell disease in the U.S., its territories and possessions, and Canada.

Revenue drivers

• NIT license and royalties — The December 2025 license with NIT provided an upfront cash payment, a double-digit percentage royalty on NIT's licensed-product sales, and a double-digit percentage of any NIT sublicense rights. Part of the upfront payment and royalties were recognized as revenue in Q2 2026, driving the quarter's revenue increase.
• U.S. Endari sales — Endari is sold through nonexclusive U.S. distributors; these sales were the historical base of revenue but declined in Q2 2026, partly offsetting the NIT-related revenue.
• MENA Endari sales — Endari is approved and sold in the U.A.E., Qatar, Kuwait, Bahrain and Oman through exclusive distributors, and is available on a named-patient basis in the KSA while marketing authorization is pending.
• Exclusive supply to NIT — An Exclusive Supply Agreement requires Emmaus to supply NIT's requirements for licensed products in the U.S./Canada territory at cost of production plus a specified double-digit percentage margin.

Recent performance

Q2 2026 net revenues were $6.3 million, up 124% from $2.8 million in Q2 2025, primarily from recognizing revenue on the NIT license arrangement, partly offset by lower direct Endari sales. Total operating expenses fell to $2.1 million from $3.0 million, mainly due to transferring the sales force to NIT. Income from operations was $3.8 million versus a $0.4 million operating loss a year earlier, and net income was $1.3 million, or $0.02 basic EPS, compared with a $1.1 million net loss. Other expense rose to $2.5 million from $1.4 million, mainly due to smaller gains on lease modification and changes in fair value of equity securities. Cash and cash equivalents were $2.8 million at June 30, 2026 versus $2.1 million at December 31, 2025.

Strategy

The central strategic move is the NIT license, which transfers U.S. and Canada commercialization rights for Endari in sickle cell disease to NIT while Emmaus retains rights outside the field and territory and becomes the exclusive supplier. Under the agreement Emmaus received an upfront cash payment, will receive double-digit percentage royalties on NIT sales and sublicenses, and is using $1.0 million of the upfront payment to subscribe for NIT shares. Pending the May 15, 2026 effective date, NIT hired selected members of Emmaus' U.S. sales force and provides sales and marketing services to Emmaus for quarterly fees in the low-to-mid six figures; Emmaus continued to book all territory Endari revenue before the effective date. Management also highlights reduced operating expenses following the sales force transfer.

Risks

• Dependence on a single product — Endari is the company's only product, so any decline in its sales, reimbursement or regulatory status directly hits total revenue.
• NIT execution and concentration — U.S. and Canada Endari revenue now depends on NIT, which the filing says has no experience marketing brand name or generic pharmaceuticals and may not successfully market or distribute the products.
• Balance sheet and negative equity — At June 30, 2026, total liabilities of $82.5 million exceeded total assets of $16.4 million, producing shareholders' equity of negative $66.2 million, with only $2.8 million of cash.
• Revenue volatility — Annual revenue fell from $29.6 million in 2023 to $16.7 million in 2024 and $12.5 million in 2025, and quarterly revenue swung from $3.9 million in Q4 2025 to $2.0 million in Q1 2026 before the license-related jump in Q2 2026.

Outlook

The 10-Q states that following the May 15, 2026 effective date of the NIT license, Emmaus' U.S. revenues will depend on NIT, and management says historical results are unlikely to indicate future performance. The company continues to pursue marketing authorization in Saudi Arabia, where Endari already has named-patient access and market exclusivity through the KSA unified purchasing system. No forward financial guidance is given in the excerpts; management's stated focus is the NIT arrangement, royalty and supply economics, and lower operating costs.